Filing Flows › Health Care › ImageneBio (IMA)
ImageneBio (IMA) earnings and revenue breakdown
Latest: Q1 2025 · 10-Q filed May 8, 2025 · ImageneBio (IMA) Q1 2025 earnings results →
ImageneBio made $800K in Q1 2025. Operating margin n/m, net loss $8.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 8, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $800K in Q1 2025.
Operating costs exceeded revenue by $10.8M, an operating margin of -1349.2%. The quarter ended with a net loss of $8.6M. Non-operating items added $2.2M, -26% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$10.6M. Non-cash charges added back $2K of depreciation and amortization and $904K of share-based compensation. Working capital and other items used $2.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 10-Q | May 8, 2025 | $800K | — | n/m | −$8.6M | −$10.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About ImageneBio
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company’s program, olevaprubart (formerly IMG-007), is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.
In its own words, from its 8-K, filed Aug 5, 2026.
ImageneBio against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IMA ImageneBio | Q1 2025 | $800K | — | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: ImageneBio 10-Q on SEC EDGAR · CIK 1835579 · Biological Products, (No Diagnostic Substances)
13F: who owns IMA and who is buying
More on IMA
History
Every quarter: Q1 2025 results